

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Application Number	10/566,501 10/566224
		Filing Date	September 14, 2007
		First Named Inventor	Martin HENDRIX, et al.
		Art Unit	1624
		Examiner Name	Rao Deepak R.
Sheet	1	of	3
		Attorney Docket Number	
		01-2118	

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
/SM/		3,165,520	01-12-1965	Paul SCHMIDT, et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
/S.M./		CA 2 484 997 A1	04-22-2003	Bayer Cropscience AG		
/S.M./		CA 2 417 631 A1	01-29-2003	Bayer Aktiengesellschaft		
		CA 2 480 000 A1	09-06-2002	Bayer Aktiengesellschaft		
		CA 2 406 104 A1	09-01-2004	Bayer Healthcare AG		
		CA 2 496 292 A1	04-01-2004	Bayer Healthcare AG		
		CA 2 406 303 A1	04-01-2004	Bayer Healthcare AG		
		CA 2 283 211 A1	09-17-1998	Bayer Aktiengesellschaft		
		CH 396 928	01-31-1966	CIBA Aktiengesellschaft		
		CH 396 924	01-31-1966	CIBA Aktiengesellschaft		
		CH 396 925	01-31-1966	CIBA Aktiengesellschaft		
		CH 396 926	01-31-1966	CIBA Aktiengesellschaft		
		CH 396 927	01-31-1966	CIBA Aktiengesellschaft		
		DE 1 150 623	08-22-1962	CIBA Aktiengesellschaft		
		DE 1 149 013	05-22-1963	CIBA Aktiengesellschaft		
		DE 2 408 906	09-10-1974	Chemische Fabrik von Heyden GmbH		
		DE 1 156 415	10-31-1962	CIBA Aktiengesellschaft		
		DE 101 56 240	05-28-2003	Bayer, AG		
		DE 1 147 234	04-18-1962	CIBA Aktiengesellschaft		
		EP 0 095 751 A2	04-26-2000	Pfizer Inc.		
		EP 0 095 751 A2	04-26-2000	Pfizer Inc.		
		GB 927 726	09-25-1963	CIBA Limited		
		GB 975,361	10-28-1964	CIBA Limited		
/S.M./		WO 2004/018474 A1	03-04-2004	Bayer Healthcare AG		
		WO 2004/028288 A0	04-01-2004	Bayer Healthcare AG		

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/S.M./		F. Josef van der STAAY, et al., "The novel selective PDE9 inhibitor BAY 73-6691 improves learning and memory in rodents", NEUROPHARMACOLOGY, 55 (2008) pp. 908-916	
/S.M./		U. EBERT, et al., "Scopolamine model of dementia: electroencephalogram findings and cognitive performance", EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, (1998) 28, pp. 944-949	
/S.M./		Jos PRICKAERTS, et al., "Possible role of nitric oxide-cyclic GMP pathway in object recognition memory: Effect of 7-nitroindazole and zaprinast", EUROPEAN JOURNAL OF PHARMACOLOGY 337 (1997) pp. 125-136	
/S.M./		F. Zaragoza DÖRWALD, "Side Reactions in Organic Synthesis", A GUIDE TO SUCCESSFUL SYNTHESIS DESIGN, 2005, 4 pages preface	
/S.M./		Kenneth F. PODRAZA, "Reductive Cyclization of Ketoesters Utilizing Sodium Cyanoborohydride: Synthesis of γ - and δ -Lactones" J. HETEROCLIC CHEM., 24, 193 (1987)	
/S.M./		Internet Article, "Amnesia", From Wikipedia, the free encyclopedia, 3 pages , downloaded 12/18/08 < file:///C:/DOCUME~1/jmurray/LOCALS~1/Temp\RRAV9XSH.htm>	
/S.M./		Reid IA, "Role of phosphodiesterase isoenzymes in the control of rennin secretion: effects of selective enzyme inhibitors", CURR PHARM DES, 1999, Sep; 5(9): 725-35 abstract	
/S.M./		Edwin J. WEEBER, et al., "Molecular Genetics of Human Cognition", MOLECULAR INVENTIONS, Vol. 2, Issue 6, October 2002, pps. 376-391	
		International Search Report for International Application No. PCT/EP2004/004455 mailed September 17, 2004, 8 pages	
		International Search Report for International Application No. PCT/EP2004/004446 mailed July 14, 2004, 6 pages	
		International Search Report for International Application No. PCT/EP02/08070 mailed November 26, 2000, 8 pages	
		International Search Report for International Application No. PCT/EP02/08020 mailed December 15, 2000, 8 pages	
		International Search Report for International Application No. PCT/EP2004/000477 mailed October 27, 2004, 8 pages	
		International Search Report for International Application No. PCT/EP2004/014872 mailed May 19, 2005, 10 pages	
		Scott H. SODERLING, et al., "Identification and Characterization of a Novel Family of Cyclic Nucleotide Phosphodiesterases", THE JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 273, No. 25, Issue of June 19, 1998, pgs. 15553-15558	
		Scott H. SODERLING, et al., "Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions", CURRENT OPINION IN CELL BIOLOGY, 2000, 12:174-179	
		Svetlana G. ANDREEVA, et al., "Expression of cGMP-Specific Phosphodiesterase 9A mRNA in the Rat Brain", THE JOURNAL OF NEUROSCIENCE, November 15, 2001, 21(22); pgs. 9068-9076	
		G. O. SHENK, et al., "Potential Purine Antagonist VII. Synthesis of 6-Alkylpurazolo[3,4-d]pyrimidines ^{12a} ", POTENTIAL PURINE ANTAGONISTS, VII, Vol. 23, February 1958, pgs. 191-200	
		Lindsay PAWCETT, et al., "Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11A", PNAS, Vol. 97, No. 7, March 28, 2000, pgs. 3702-3707	
		Douglas A. FISHER, et al., "Isolation and Characterization of PDE9A, a Novel Human cGMP-specific Phosphodiesterase", THE JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 273, No. 25, Issue of June 19, 1998, pgs. 15559-15564	
		Douglas A. FISHER, et al., "Isolation and Characterization of PDE8A, a Novel Human cAMP-Specific Phosphodiesterase", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, Vol. 246, April 15, 1998, pgs. 570-577	
		Sharron H. FRANCAIS, et al., "Characterization of a Novel cGMP Binding Protein from Rat Lung", THE JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 255, No. 2, Issue of January 25, 1980, pgs. 620-626	
		Kotomi FUJISHIGE, et al., "Cloning and Characterization of a Novel Human Phosphodiesterase That Hydrolyzes Both cAMP and cGMP (PDE10A)", THE JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 274, No. 29, Issue of June 25, 1999, pgs. 18438-18445	
		Heike GIELEN, et al., "A novel approach to amidines from esters", TETRAHEDRON LETTERS, 42, 2000, pgs. 419-421	
		Rudolf COMPREITER, et al., "Substituted ethylene boronic acids and ketene thioactals", CARBOXYLIC ACID DERIVATIVES, Vol. 95, 1962, pgs. 2861-2870	

	Peter G. CHILDEWIE, et al., "Characterization of a Bovine Cone Photoreceptor Phosphodiesterase Purified by Cyclic GMP-Sepharose Chromatography", THE JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 263, No. 7, Issue of June 15, 1988, pgs. 8133-8141	
	Michel GHIBBIOLI, et al., "Identification and characterization of a novel cyclic nucleotide phosphodiesterase gene (PDE9A) that maps to 21q22.3: alternative splicing of mRNA transcripts, genomic structure and sequence", HUMAN GENET (1998) 103:386-392	
	J. M. HETTMANZ, et al., "Cloning and characterization of PDE7B, a cAMP-specific phosphodiesterase", PHARMACOLOGY, Vol. 97, No. 1, January 4, 2000, pgs. 472-476	
	Kate LOUGHNEY, et al., "Isolation and characterization of cDNAs Corresponding to Two Human Calcium, Calmodulin-regulated, 3',5'-Cyclic Nucleotide Phosphodiesterases", THE JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 271, No. 2, Issue of January 12, 1996, pgs. 796-806	
	James E. HOETTLER, et al., "Primary Culture of Identified Neurons from the Visual Cortex of Postnatal Rats", THE JOURNAL OF NEUROSCIENCE, Vol. 6, No. 10, pgs. 3044-3060	
	Kate LOUGHNEY, et al., "Isolation and characterization of cDNAs encoding PDE5A, a human cGMP-binding, cGMP-specific 3',5'-cyclic nucleotide phosphodiesterase", GENE, 216 (1998), pgs. 139-147	
	Chris LUCHNER, "Cyclic nucleotide phosphodiesterase (PDE) superfamily: A new target for the development of specific therapeutic agents", PHARMACOLOGY & THERAPEUTICS, 109 (2006), pgs. 366-398	

*Note; only structures were considered.

Examiner Signature	/Susanna Moore/	Date Considered	06/01/2009
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.